Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

TORONTO, April 19, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced today the filing of a new provisional patent application that covers new […]